サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1439586

慢性閉塞性肺疾患（COPD）治療機器 - 世界市場の考察、競合情勢、市場予測（2030年）

Chronic Obstructive Pulmonary Disease Treatment Devices - Market Insights, Competitive Landscape, and Market Forecast - 2030
出版日: 受注後更新 | 発行: DelveInsight | ページ情報: 英文 150 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
慢性閉塞性肺疾患（COPD）治療機器 - 世界市場の考察、競合情勢、市場予測（2030年）
出版日: 受注後更新
発行: DelveInsight
ページ情報: 英文 150 Pages
納期: 2～10営業日
ご注意事項 :
本レポートの納品は、最新情報反映のため受注時に適宜更新しお届けいたします。
更新情報の反映作業にあたり納期もレポート毎に異なりますので、ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の慢性閉塞性肺疾患（COPD）治療機器の市場規模は、2024年～2030年の予測期間にCAGRで6.37％の成長が見込まれます。慢性閉塞性肺疾患（COPD）治療機器に対する需要の増加は主に、大気汚染、空気中の粒子、化学品や煙、副流煙、工業用化学品や粉塵への曝露の増加による、世界中でのCOPDの有病率の増加によるものです。さらに、若者の間でタバコの消費が増加することで、COPDや喘息などの呼吸器疾患のリスクが高まり、COPD治療機器の需要が増加します。さらに、発作時の短期的かつ効果的な治療に対する需要の急増や、理想的なエアロゾル粒子径の生成と、より多くの投与量を提供する特性などの機器の技術の進歩、世界中でのCOPDや喘息のような疾患の症状や治療に対する意識の高まりが市場を強化すると予測され、それによって2024年～2030年の予測期間における慢性閉塞性肺疾患（COPD）治療機器市場の成長に寄与します。

慢性閉塞性肺疾患（COPD）治療機器の市場力学

慢性閉塞性肺疾患（COPD）治療機器市場は、大気汚染、副流煙、粉塵、煙、化学品への長期の暴露によるCOPDの有病率の増加などのさまざまな理由により製品需要が伸びています。さらに、若者の間でタバコの消費が増加していることも、予測期間中の慢性閉塞性肺疾患（COPD）治療機器市場を強化すると見込まれています。

例えば、世界保健機関（WHO）（2022）が公開したデータによると、COPDは世界第3位の死因であり、2019年に323万人の死亡を引き起こしたと推定されています。さらに、COPDによる死亡の90％近くは、低中所得国の70歳未満の患者でした。さらにCOPDは、呼吸困難、咳、痰の発生など、持続的かつ進行性の呼吸器症状を引き起こします。この疾患は、有害なガスや微粒子への長期の暴露と、小児期の肺の成長に影響するイベントや遺伝などの個人的要因が組み合わさって生じます。COPDの罹患率や死亡率を低下させるためには、早期診断と禁煙支援を含む治療が必要です。しかし、COPDの有病率の増加は、吸入器やネブライザーなどの治療機器の需要を増加させ、それによって2022年～2028年の予測期間におけるCOPD治療機器の全体的な市場成長を促進する見込みです。

さらに、American Lung Association, State of Tobacco Control（2022）によると、2022年の調査では、メンソールタバコが2022年にアフリカ系アメリカ人の新規喫煙者150万人の原因となっていることがわかっています。この研究では、2019年～2022年に、高校生の電子タバコ使用者では使い捨て電子タバコの使用率が23倍以上（2.4％から55.8％）、中学生の電子タバコ使用者では14倍以上（3％から43.8％）に急増したと結論づけています。さらに、National Youth Tobacco Survey （2020）によると、2020年～2022年に米国の高校生の23.6％以上が、電子タバコを含む少なくとも1つのタバコ製品を使用すると推定されています。同じ資料によれば、喫煙は米国における予防可能な死因の第1位であり、年間48万人以上が死亡しています。さらに、COPDは通常タバコの喫煙によって引き起こされますが、副流煙のような他の肺刺激物質への長期の暴露もCOPDの原因となります。喫煙は気嚢、気道、肺の内膜を傷つけ、COPDやその他の呼吸器疾患を引き起こしやすくします。喫煙はCOPDの再燃の引き金にもなります。傷ついた肺は十分な空気の出入りができなくなり、呼吸が苦しくなります。これはCOPDの主な症状の1つです。さらに、小児期や10代の喫煙や副流煙への暴露は、肺の成長や発達を遅らせる可能性があります。世界中での喫煙の増加はCOPDの有病率を高め、治療機器の需要急増につながり、結果としてCOPD治療機器の市場全体の成長を後押しします。

しかし、慢性閉塞性肺疾患（COPD）治療機器の高いコストや、厳しい政府規制、定量噴霧式吸入器（MDI）に関連する環境上の懸念が、慢性閉塞性肺疾患（COPD）治療機器市場成長の一定の抑制要因となる可能性があります。

当レポートでは、世界の慢性閉塞性肺疾患（COPD）治療機器市場について調査分析し、市場規模と予測、促進要因と課題、企業と製品のプロファイルなどを提供しています。

目次

第1章 慢性閉塞性肺疾患（COPD）治療機器市場レポートのイントロダクション

第2章 慢性閉塞性肺疾患（COPD）治療機器市場のエグゼクティブサマリー

  • 調査範囲
  • 市場の概要
  • 競合の評価

第3章 規制分析

  • 米国
  • 欧州
  • 日本
  • 中国

第4章 慢性閉塞性肺疾患（COPD）治療機器市場の主な要因の分析

  • 慢性閉塞性肺疾患（COPD）治療機器市場の促進要因
    • 化学品、汚染、浮遊粒子などへの曝露の増加による慢性閉塞性肺疾患（COPD）の有病率の増加
    • 若者のタバコ消費の増加
    • 発作時の短期的かつ効果的な治療に対する需要の急増
    • 理想的なエアロゾル粒子径の生成などの機器の技術の進歩
  • 慢性閉塞性肺疾患（COPD）治療機器市場の抑制要因と課題
    • 慢性閉塞性肺疾患（COPD）治療機器の高いコスト
    • 政府の厳しい規制
    • 定量噴霧式吸入器（MDI）に関連する環境上の懸念
  • 慢性閉塞性肺疾患（COPD）治療機器市場の機会
    • 意識とポータブル吸入器の需要の高まり
    • COPDと喘息の症状に対する認知の拡大に向けた政府の取り組みの高まり

第5章 慢性閉塞性肺疾患（COPD）治療機器市場のポーターのファイブフォース分析

第6章 慢性閉塞性肺疾患（COPD）治療機器市場に対するCOVID-19の影響の分析

第7章 慢性閉塞性肺疾患（COPD）治療機器市場のレイアウト

  • 製品タイプ別
    • 吸入器
    • ネブライザー
  • エンドユーザー別
    • 病院、診療所
    • 在宅ケア環境
    • その他
  • 地域別
    • 北米
    • 欧州
    • アジア太平洋
    • その他の地域

第8章 慢性閉塞性肺疾患（COPD）治療機器市場：世界の企業シェア分析 - 主要3～5社

第9章 慢性閉塞性肺疾患（COPD）治療機器市場の企業と製品のプロファイル

  • Koninklijke Philips N.V.
  • Omron Healthcare, Inc.
  • Aerogen
  • PARI GmbH
  • GF Health Products, Inc.
  • BMC Medical Co., Ltd.
  • Medtronic PLC
  • Invacare Corporation
  • Trudell Medical International
  • Nouvag AG
  • Timesco Healthcare Ltd.
  • LAICA S.p.A.
  • Vega Technologies Inc.
  • Besco Medical Limited
  • DeVilbiss Healthcare LLC
  • Feellife Health Inc.
  • Wellinks
  • Rossmax International Ltd
  • Novartis AG
  • AstraZeneca
  • GlaxoSmithKline plc
  • Lupin
  • Zydus Cadila
  • Teva Pharmaceutical Industries Ltd.
  • Boehringer Ingelheim International GmbH
  • Glenmark Pharmaceuticals Limited
  • Lepu Medical Technology (Beijing) Co., Ltd.
  • Promed Technology Co. Limited
  • HELTMAN Medikal A.S.
  • Pneuma Respiratory
  • Cipla Inc.
  • Microlife Corporation
  • Honsun

第10章 KOLの見解

第11章 プロジェクトのアプローチ

第12章 DelveInsightについて

第13章 免責事項と連絡先

図表

List of Tables

  • Table 1: Competitive Analysis
  • Table 2: COVID-19 Impact Analysis
  • Table 3: Chronic Obstructive Pulmonary Disease Treatment Devices Market in Global (2021-2030)
  • Table 4: Chronic Obstructive Pulmonary Disease Treatment Devices Market in Global by Product Type (2021-2030)
  • Table 5: Chronic Obstructive Pulmonary Disease Treatment Devices Market in Global by End User (2021-2030)
  • Table 6: Chronic Obstructive Pulmonary Disease Treatment Devices Market in Global by Geography (2021-2030)
  • Table 7: Chronic Obstructive Pulmonary Disease Treatment Devices Market in North America (2021-2030)
  • Table 8: Chronic Obstructive Pulmonary Disease Treatment Devices Market in North America by Country (2021-2030)
  • Table 9: Chronic Obstructive Pulmonary Disease Treatment Devices Market in the US (2021-2030)
  • Table 10: Chronic Obstructive Pulmonary Disease Treatment Devices Market in Canada (2021-2030)
  • Table 11: Chronic Obstructive Pulmonary Disease Treatment Devices Market in Mexico (2021-2030)
  • Table 12: Chronic Obstructive Pulmonary Disease Treatment Devices Market in Europe (2021-2030)
  • Table 13: Chronic Obstructive Pulmonary Disease Treatment Devices Market in Europe by Country (2021-2030)
  • Table 14: Chronic Obstructive Pulmonary Disease Treatment Devices Market in France (2021-2030)
  • Table 15: Chronic Obstructive Pulmonary Disease Treatment Devices Market in Germany (2021-2030)
  • Table 16: Chronic Obstructive Pulmonary Disease Treatment Devices Market in the United Kingdom (2021-2030)
  • Table 17: Chronic Obstructive Pulmonary Disease Treatment Devices Market in Italy (2021-2030)
  • Table 18: Chronic Obstructive Pulmonary Disease Treatment Devices Market in Spain (2021-2030)
  • Table 19: Chronic Obstructive Pulmonary Disease Treatment Devices Market in Russia (2021-2030)
  • Table 20: Chronic Obstructive Pulmonary Disease Treatment Devices Market in Rest of Europe (2021-2030)
  • Table 21: Chronic Obstructive Pulmonary Disease Treatment Devices Market in APAC (2021-2030)
  • Table 22: Chronic Obstructive Pulmonary Disease Treatment Devices Market in APAC by Country (2021-2030)
  • Table 23: Chronic Obstructive Pulmonary Disease Treatment Devices Market in China (2021-2030)
  • Table 24: Chronic Obstructive Pulmonary Disease Treatment Devices Market in Japan (2021-2030)
  • Table 25: Chronic Obstructive Pulmonary Disease Treatment Devices Market in India (2021-2030)
  • Table 26: Chronic Obstructive Pulmonary Disease Treatment Devices Market in Australia (2021-2030)
  • Table 27: Chronic Obstructive Pulmonary Disease Treatment Devices Market in South Korea (2021-2030)
  • Table 28: Chronic Obstructive Pulmonary Disease Treatment Devices Market in Rest of APAC (2021-2030)
  • Table 29: Chronic Obstructive Pulmonary Disease Treatment Devices Market in Rest of World (2021-2030)
  • Table 30: Chronic Obstructive Pulmonary Disease Treatment Devices Market in RoW by Region (2021-2030)

List of Figures

  • Figure 1: Competitive Analysis
  • Figure 2: COVID-19 Impact Analysis
  • Figure 3: Chronic Obstructive Pulmonary Disease Treatment Devices Market in Global (2021-2030)
  • Figure 4: Chronic Obstructive Pulmonary Disease Treatment Devices Market in Global by Product Type (2021-2030)
  • Figure 5: Chronic Obstructive Pulmonary Disease Treatment Devices Market in Global by End User (2021-2030)
  • Figure 6: Chronic Obstructive Pulmonary Disease Treatment Devices Market in Global by Geography (2021-2030)
  • Figure 7: Chronic Obstructive Pulmonary Disease Treatment Devices Market in North America (2021-2030)
  • Figure 8: Chronic Obstructive Pulmonary Disease Treatment Devices Market in North America by Country (2021-2030)
  • Figure 9: Chronic Obstructive Pulmonary Disease Treatment Devices Market in the US (2021-2030)
  • Figure 10: Chronic Obstructive Pulmonary Disease Treatment Devices Market in Canada (2021-2030)
  • Figure 11: Chronic Obstructive Pulmonary Disease Treatment Devices Market in Mexico (2021-2030)
  • Figure 12: Chronic Obstructive Pulmonary Disease Treatment Devices Market in Europe (2021-2030)
  • Figure 13: Chronic Obstructive Pulmonary Disease Treatment Devices Market in Europe by Country (2021-2030)
  • Figure 14: Chronic Obstructive Pulmonary Disease Treatment Devices Market in France (2021-2030)
  • Figure 15: Chronic Obstructive Pulmonary Disease Treatment Devices Market in Germany (2021-2030)
  • Figure 16: Chronic Obstructive Pulmonary Disease Treatment Devices Market in the United Kingdom (2021-2030)
  • Figure 17: Chronic Obstructive Pulmonary Disease Treatment Devices Market in Italy (2021-2030)
  • Figure 18: Chronic Obstructive Pulmonary Disease Treatment Devices Market in Spain (2021-2030)
  • Figure 19: Chronic Obstructive Pulmonary Disease Treatment Devices Market in Russia (2021-2030)
  • Figure 20: Chronic Obstructive Pulmonary Disease Treatment Devices Market in Rest of Europe (2021-2030)
  • Figure 21: Chronic Obstructive Pulmonary Disease Treatment Devices Market in APAC (2021-2030)
  • Figure 22: Chronic Obstructive Pulmonary Disease Treatment Devices Market in APAC by Country (2021-2030)
  • Figure 23: Chronic Obstructive Pulmonary Disease Treatment Devices Market in China (2021-2030)
  • Figure 24: Chronic Obstructive Pulmonary Disease Treatment Devices Market in Japan (2021-2030)
  • Figure 25: Chronic Obstructive Pulmonary Disease Treatment Devices Market in India (2021-2030)
  • Figure 26: Chronic Obstructive Pulmonary Disease Treatment Devices Market in Australia (2021-2030)
  • Figure 27: Chronic Obstructive Pulmonary Disease Treatment Devices Market in South Korea (2021-2030)
  • Figure 28: Chronic Obstructive Pulmonary Disease Treatment Devices Market in Rest of APAC (2021-2030)
  • Figure 29: Chronic Obstructive Pulmonary Disease Treatment Devices Market in Rest of World (2021-2030)
  • Figure 30: Chronic Obstructive Pulmonary Disease Treatment Devices Market in RoW by Region (2021-2030)
  • Figure 31: Market Drivers
  • Figure 32: Market Barriers
  • Figure 33: Marker Opportunities
  • Figure 34: PORTER'S Five Force Analysis
目次
Product Code: DIMDCL0416

Chronic Obstructive Pulmonary Disease Treatment Devices Market By Product Type (Inhalers [Dry Powder Inhaler, Metred Dose Inhaler, And Soft Mist Inhalers] And Nebulizers [Compressor Nebulizer, Ultrasonic Nebulizer, And Mesh Nebulizer]), By End-User (Hospitals & Clinics, Homecare Settings, And Other End-Users), by geography is expected to grow at a steady CAGR forecast till 2030 owing to growing prevalence of chronic obstructive pulmonary diseases due to long-term exposure to air pollution, secondhand smoke & dust, fumes & chemicals and rise in consumption of tobacco among youth population

Global chronic obstructive pulmonary disease (COPD) treatment devices market is estimated to grow at a CAGR of 6.37% during the forecast period from 2024 to 2030. The increase in demand for chronic obstructive pulmonary disease treatment devices is primarily attributed to the rising exposure to air pollution, airborne particles, chemicals & fumes, secondhand smoke, industrial chemicals and dust owing to which the prevalence of COPD is increasing globally. Further, rise in consumption of tobacco among youth population will increase the risk of respiratory disorders like COPD, asthma ultimately leading to propel the demand of COPD treating devices. Additionally, the burgeoning demand for short-term and effective treatment in case of attacks, technological advancements in the devices such as production of ideal aerosol particle size & property of providing higher amount of dose, and others, and increasing awareness about the symptoms and treatment of disorders like COPD and asthma across the world are anticipated to bolster the market, thereby contributing to the growth of the chronic obstructive pulmonary disease treatment devices market during the forecast period from 2024-2030.

Chronic Obstructive Pulmonary Disease Treatment Devices Market Dynamics:

The chronic obstructive pulmonary disease treatment devices market is witnessing a growth in product demand owing to various reasons such as the growing prevalence of COPD due to long-term exposure to air pollution, secondhand smoke and dust, fumes and chemicals. Furthermore, rise in consumption of tobacco among youth population is anticipated to bolster the market for chronic obstructive pulmonary disease treatment devices during the forecast period.

For instance, according to the data published by World Health Organization (WHO) 2022, it was estimated that COPD was the third leading cause of death worldwide, causing 3.23 million deaths in the year 2019. Additionally, nearly 90% of COPD deaths were those in patients under 70 years of age in low- and middle-income countries. Moreover, COPD causes persistent and progressive respiratory symptoms, including difficulty in breathing, cough and phlegm production. The disorder results from long-term exposure to harmful gases and particles combined with individual factors, including events which influence lung growth in childhood and genetics. Early diagnosis and treatment, including smoking cessation support is required to slow down the incidence and mortality rate from the disease. However, the increasing prevalence of COPD will increase the demand of treatment devices such as inhalers and nebulizers, thereby expected to propel the overall market growth of the COPD treatment devices in the forecast period of 2022 - 2028.

Moreover, according to American Lung Association, State of Tobacco Control 2022, a 2022 study found that menthol cigarettes were responsible for 1.5 million new smokers among African Americans in 2022. The study concluded that from 2019 to 2022, disposable e-cigarette use skyrocketed by more than 23 times among high school e-cigarette users (from 2.4% to 55.8%) and more than 14 times among middle school e-cigarette users (from 3% to 43.8%). Additionally, according to National Youth Tobacco Survey 2020, it was estimated that in 2020-2022 more than 23.6% of high school students in the U.S. use at least one tobacco product, including e-cigarettes. As per the same source, smoking is the number one preventable cause of death in the U.S. killing over 480,000 people per year. Furthermore, COPD is usually caused by cigarette smoking, though long-term exposure to other lung irritants, like secondhand smoke, can also contribute to COPD. Smoking damages the air sacs, airways, and the lining of the lungs making it sensitive for COPD and other respiratory disorders. Smoking is also a trigger for COPD flare-ups. Injured lungs have trouble moving enough air in and out, so it's hard to breathe; one of the major symptoms of COPD. Moreover, smoking and secondhand smoke exposure during childhood and teenage years can slow lung growth and development. The rising consumption of smoking globally will increase the prevalence of COPD, leading to the surging demand of the treatment devices ultimately bolstering the overall market growth of COPD treating devices.

However, high cost of chronic obstructive pulmonary disease treatment devices, stringent government regulations, and environmental concerns associated with metered dose inhalers (MDI) may be certain limiting factors of the chronic obstructive pulmonary disease treatment devices market growth.

The ongoing COVID-19 pandemic had a drastic positive impact on the chronic obstructive pulmonary disease treatment devices market owing to rising burden of the respiratory diseases in COVID-19 pandemic as the viral infection severely affects the lungs. Moreover, it is estimated that people may develop respiratory illness such as COPD and others as an after effect which will surge the demand for the devices among the COVID recovering patients. However, due to strict lockdown restrictions there were disruption in the supply chain leading to unavailability of raw materials halting the manufacturing process. This lead to shortage of device and higher prices of device in the market. However, with masses being vaccinated, and resumption of the cross border trade and supply chain, and with the increasing demand the key players of the chronic obstructive pulmonary disease treatment devices market increased their manufacturing across the world are anticipated to bolster the market, thereby contributing to the growth of the chronic obstructive pulmonary disease treatment devices market during the forecast period from 2024-2030.

Chronic Obstructive Pulmonary Disease Treatment Devices Market Segment Analysis:

Chronic Obstructive Pulmonary Disease Treatment Devices Market by Product Type (Inhalers [Dry Powder Inhaler, Metered Dose Inhaler, and Soft Mist Inhalers] and Nebulizers [Compressor Nebulizer, Ultrasonic Nebulizer, and Mesh Nebulizer]), by End-User (Hospitals & Clinics, Homecare Settings, and Other End Users) and by Geography (North America, Europe, Asia-Pacific, and Rest of the World).

In the product type segment of the chronic obstructive pulmonary disease treatment devices market, the soft mist inhalers is estimated to hold a higher share in the chronic obstructive pulmonary disease treatment devices market in the year 2023. This can be ascribed to the wide benefit circle that is associated with the soft mist inhalers.

The soft mist inhalers is one of the newer type of device. It creates a cloud of medicine that a patient can inhale without the help of a propellant. The mist in the inhaler contains more particles than the other types of inhalers.

Moreover, the spray in the soft mist inhalers leaves the inhaler more slowly leading to more of the drug into the lungs. Additionally, as the mist comes out slowly so the device doesn't require any coordination while inhaling the drug. A spacer is also unnecessary in case of soft mist inhalers.

Further, the soft mist inhaler is portable and comes with a combination of drug molecules available in the market. The inhaler is inspiratory flow independent, no maximum flow is required at the time of the deliver and comes with once-daily dosing.

Moreover, the product launches in local market, in turn, drive the product demand in the market. For instance, in December 2022, Boehringer Ingelheim, one of the world's largest pharmaceutical companies, announced the launch of the Respimat® reusable inhaler in Ireland. The inhaler is a soft mist, reusable inhaler used with up to six refill cartridges. It is a propellant-free inhaler. By using the reusable inhaler with six refill cartridges the product carbon footprint is reduced by 71%. The inhaler delivers the chronic obstructive pulmonary disease (COPD) as well as the asthma medication.

Thus, owing to the wide advantages as well as product launch in the local market will increase the demand of soft mist inhalers, which in turn will drive the overall chronic obstructive pulmonary disease treatment devices market growth.

North America is expected to dominate the overall Chronic Obstructive Pulmonary Disease Treatment Devices Market:

Among all the regions, North America is expected to account for the largest share in the global Chronic Obstructive Pulmonary Disease Treatment Devices market. Growing prevalence of chronic obstructive pulmonary disease due to exposure to air pollution, airborne particles, chemicals & fumes, secondhand smoke, industrial chemicals & dust and rise in consumption of tobacco among youth population will drive the demand for chronic obstructive pulmonary disease treatment devices in the forecast period. Further, government initiations to create the awareness of diagnosis and treatment of COPD, leading to increased demand of treatment devices in the market. Thus, leading to a rise in the overall North America chronic obstructive pulmonary disease treatment devices market growth.

For instance, according the Center for Disease Control and Prevention (CDC) 2020, it was estimated that percentage of COPD, emphysema, or chronic bronchitis for adults aged 18 and over in the United States in the year 2020 was 5.0%. Moreover, according Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease, Report 2022, reported that the prevalence of COPD is higher in smokers & ex-smokers as compared to non-smokers in the United States. The morbidity of COPD may be affected by other chronic diseases such as, cardiovascular diseases, musculoskeletal impairment, diabetes, and others that are related to smoking, age and genetics. Additionally, as per CDC 2020, the number of deaths in the year 2020 due to bronchitis was nearly 457 in US. Further, emphysema deaths in the year 2020 in US was nearly 7,425. The increasing prevalence and mortality rate can be slowed down by giving proper treatment to the patients by using the treatment devices such as, inhalers and nebulizers, ultimately leading to increase demand of COPD treating devices. Thus, the increasing prevalence of COPD in the United States is anticipated to bolster the COPD treatment devices market in the forecast period, thereby increasing the overall market growth in the North America.

Furthermore, according to United States Environmental Protection Agency 2022, in the year 2023, it was calculated that about 67 million tons of pollution were emitted into the atmosphere in the United States. Breathing in air pollutants can irritate the airways and may cause shortness of breath, coughing, and wheezing. People with chronic respiratory diseases such as chronic obstructive pulmonary disease (COPD) are vulnerable to the detrimental effects of air pollutants. Air pollution can induce the acute exacerbation of COPD and can increase the respiratory morbidity and mortality. The increasing air pollution may increase the incidence and exacerbation of COPD, leading to the increased demand of COPD treating devices like inhalers and nebulizers in the market. Thus, increasing the market of the devices in the forecast period 2022 - 2028. Therefore, propelling the overall market growth of the chronic obstructive pulmonary disease treatment devices in the North America.

Thus, all the above-mentioned factors will collectively contribute to the chronic obstructive pulmonary disease treatment devices market growth in the North America region.

Chronic Obstructive Pulmonary Disease Treatment Devices Market Key Players:

Some of the key market players operating in the chronic obstructive pulmonary disease treatment devices market include Koninklijke Philips N.V., Omron Healthcare, Inc., Aerogen, PARI GmbH, GF Health Products, Inc., BMC Medical Co., Ltd., Medtronic PLC, Invacare Corporation, Trudell Medical International, Nouvag AG, Timesco Healthcare Ltd., LAICA S.p.A., Vega Technologies Inc., Besco Medical Limited, DeVilbiss Healthcare LLC, Feellife Health Inc., Wellinks, Rossmax International Ltd., Novartis AG, AstraZeneca, GlaxoSmithKline plc, Lupin, Zydus Cadila, Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim International GmbH, Glenmark Pharmaceuticals Limited, LepuMedical Technology(Beijing)Co.,Ltd., Promed Technology Co. Limited, HELTMAN Medikal A.S., Pneuma Respiratory, Cipla Inc., Microlife Corporation, Honsun, among others.

Recent Developmental Activities in the Chronic Obstructive Pulmonary Disease Treatment Devices Market:

In August 2022, Lupin Healthcare Limited, wholly-owned subsidiary of global pharma major Lupin Limited, announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has approved its Luforbec® (beclometasone/formoterol) 100/6 dose pressurized metered dose inhaler (pMDI) for the patients in the UK. Luforbec is indicated for the treatment of adult asthma and for the symptomatic treatment of severe chronic obstructive pulmonary disease (COPD).

In January 2022, Wellinks, the nebulizer's developer, announced that the wireless nebulizer for use by people with chronic obstructive pulmonary disease (COPD) has been cleared by a review board of the U.S. Food and Drug Administration (FDA).

In October 2020, Zydus Cadila, Indian multinational pharmaceutical company, announced that they had launched Forglyn pMDI, a pressurized Metered Dose Inhaler (pMDI) with a combination of Long Acting Muscarinic Antagonist (LAMA) and Long Acting Beta Agonist (LABA) for patients suffering from Chronic Obstructive Pulmonary Disease (COPD) in India.

In July 2020, AstraZeneca's, a global, science-led biopharmaceutical company, announced that its Breztri Aerosphere inhaler has been approved in the US for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

Key Takeaways from the Chronic Obstructive Pulmonary Disease Treatment Devices Market Report Study

  • Market size analysis for current chronic obstructive pulmonary disease treatment devices market size (2023), and market forecast for 5 years (2024-2030)
  • The effect of the COVID-19 pandemic on this market is significant. To capture and analyze suitable indicators, our experts are closely watching the chronic obstructive pulmonary disease treatment devices market.
  • Top key product/services/technology developments, merger, acquisition, partnership, joint venture happened for last 3 years
  • Key companies dominating the global chronic obstructive pulmonary disease treatment devices market.
  • Various opportunities available for the other competitor in the chronic obstructive pulmonary disease treatment devices market space.
  • What are the top performing segments in 2023? How these segments will perform in 2030.
  • Which is the top-performing regions and countries in the current chronic obstructive pulmonary disease treatment devices market scenario?
  • Which are the regions and countries where companies should have concentrated on opportunities for chronic obstructive pulmonary disease treatment devices market growth in the coming future?

Target Audience who can be benefited from this Chronic Obstructive Pulmonary Disease Treatment Devices Market Report Study

  • Chronic obstructive pulmonary disease treatment devices providers
  • Research organizations and consulting companies
  • Chronic obstructive pulmonary disease treatment devices-related organizations, associations, forums, and other alliances
  • Government and corporate offices
  • Start-up companies, venture capitalists, and private equity firms
  • Distributors and Traders dealing in chronic obstructive pulmonary disease treatment devices
  • Various End-users who want to know more about the chronic obstructive pulmonary disease treatment devices market and latest technological developments in the chronic obstructive pulmonary disease treatment devices market.

Frequently Asked Questions for Chronic Obstructive Pulmonary Disease Treatment Devices Market:

1. What are Chronic Obstructive Pulmonary Disease Treatment Devices?

Chronic obstructive pulmonary disease treatment devices are the medical devices or tools used by a patient to treat the symptoms of chronic obstructive pulmonary disease. The medication to treat COPD is administrated through a device such as, inhalers, used to get relief from the symptoms of the disease.

2. What is the market for Global Chronic Obstructive Pulmonary Disease Treatment Devices?

Global chronic obstructive pulmonary disease (COPD) treatment devices market is estimated to grow at a CAGR of 6.37% during the forecast period from 2024 to 2030.

3. What are the drivers for the Global Chronic Obstructive Pulmonary Disease Treatment Devices market?

The chronic obstructive pulmonary disease treatment devices market is witnessing a positive market growth owing to growing prevalence of chronic obstructive pulmonary disease, rise in consumption of tobacco among youth population, increasing exposure to chemicals, pollution, airborne particles, and others, and burgeoning demand for short-term and effective treatment in case of attacks across the world are anticipated to bolster the market.

4. Who are the key players operating in the Global Chronic Obstructive Pulmonary Disease Treatment Devices market?

Some of the key market players operating in the chronic obstructive pulmonary disease treatment devices market include Koninklijke Philips N.V., Omron Healthcare, Inc., Aerogen, PARI GmbH, GF Health Products, Inc., BMC Medical Co., Ltd., Medtronic PLC, Invacare Corporation, Trudell Medical International, Nouvag AG, Timesco Healthcare Ltd., LAICA S.p.A., Vega Technologies Inc., Besco Medical Limited, DeVilbiss Healthcare LLC, Feellife Health Inc., Wellinks, Rossmax International Ltd., Novartis AG, AstraZeneca, GlaxoSmithKline plc, Lupin, Zydus Cadila, Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim International GmbH, Glenmark Pharmaceuticals Limited, LepuMedical Technology(Beijing)Co.,Ltd., Promed Technology Co. Limited, HELTMAN Medikal A.S., Pneuma Respiratory, Cipla Inc., Microlife Corporation, Honsun and others.

5. Which region has the highest share in Chronic Obstructive Pulmonary Disease Treatment Devices Market?

North America is expected to hold the highest revenue share in the chronic obstructive pulmonary disease treatment devices market during the forecast period. Growing prevalence of chronic obstructive pulmonary disease and rise in consumption of tobacco among youth population, will increase the demand for chronic obstructive pulmonary disease treatment devices in North America, leading to a rise in the overall chronic obstructive pulmonary disease treatment devices market growth in this region.

Table of Contents

1.Chronic Obstructive Pulmonary Disease Treatment Devices Market Report Introduction

2.Chronic Obstructive Pulmonary Disease Treatment Devices Market Executive Summary

  • 2.1. Scope of the Study
  • 2.2. Market at Glance
  • 2.3. Competitive Assessment

3. Regulatory Analysis

  • 3.1. The United States
  • 3.2. Europe
  • 3.3. Japan
  • 3.4. China

4. Chronic Obstructive Pulmonary Disease Treatment Devices Market Key Factors Analysis

  • 4.1. Chronic Obstructive Pulmonary Disease Treatment Devices Market Drivers
    • 4.1.1. Growing Prevalence of Chronic Obstructive Pulmonary Disease Due to Increasing Exposure to Chemicals, Pollution, Airborne Particles, and Others
    • 4.1.2. Rise in Consumption of Tobacco Among Youth Population
    • 4.1.3. Burgeoning Demand for Short-Term and Effective Treatment in Case of Attacks
    • 4.1.4. Technological Advancements in the Devices Such as Production of Ideal Aerosol Particle Size
  • 4.2. Chronic Obstructive Pulmonary Disease Treatment Devices Market Restraints and Challenges
    • 4.2.1. High Cost of Chronic Obstructive Pulmonary Disease Treatment Devices
    • 4.2.2. Stringent Government Regulations
    • 4.2.3. Environmental Concerns Associated with Metered Dose Inhalers (MDI)
  • 4.3. Chronic Obstructive Pulmonary Disease Treatment Devices Market Opportunities
    • 4.3.1. Increasing Awareness and Demand of Portable Inhalation Devices
    • 4.3.2. Rising Government Initiatives Toward the Spread of Awareness for COPD and Asthma Symptoms

5. Chronic Obstructive Pulmonary Disease Treatment Devices Market Porter's Five Forces Analysis

  • 5.1. Bargaining Power of Suppliers
  • 5.2. Bargaining Power of Consumers
  • 5.3. Threat of New Entrants
  • 5.4. Threat of Substitutes
  • 5.5. Competitive Rivalry

6. COVID-19 Impact Analysis on Chronic Obstructive Pulmonary Disease Treatment Devices Market

7. Chronic Obstructive Pulmonary Disease Treatment Devices Market Layout

  • 7.1. By Product Type
    • 7.1.1. Inhalers
      • 7.1.1.1. Dry Powder Inhaler
      • 7.1.1.2. Metered Dose Inhaler
      • 7.1.1.3. Soft Mist Inhalers
    • 7.1.2. Nebulizers
      • 7.1.2.1. Compressor Nebulizer
      • 7.1.2.2. Ultrasonic Nebulizer
      • 7.1.2.3. Mesh Nebulizer
  • 7.2. By End-User
    • 7.2.1. Hospitals & Clinics
    • 7.2.2. Homecare Settings
    • 7.2.3. Others
  • 7.3. By Geography
    • 7.3.1. North America
      • 7.3.1.1. United States
      • 7.3.1.2. Canada
      • 7.3.1.3. Mexico
    • 7.3.2. Europe
      • 7.3.2.1. France
      • 7.3.2.2. Germany
      • 7.3.2.3. United Kingdom
      • 7.3.2.4. Italy
      • 7.3.2.5. Spain
      • 7.3.2.6. Rest of Europe
    • 7.3.3. Asia-Pacific
      • 7.3.3.1. China
      • 7.3.3.2. Japan
      • 7.3.3.3. India
      • 7.3.3.4. Australia
      • 7.3.3.5. South Korea
      • 7.3.3.6. Rest of Asia Pacific
    • 7.3.4. Rest of the World (RoW)

8. Chronic Obstructive Pulmonary Disease Treatment Devices Market Global Company Share Analysis - Key 3-5 Companies

9. Chronic Obstructive Pulmonary Disease Treatment Devices Market Company and Product Profiles

  • 9.1. Koninklijke Philips N.V.
    • 9.1.1. Company Overview
    • 9.1.2. Company Snapshot
    • 9.1.3. Financial Overview
    • 9.1.4. Product Listing
    • 9.1.5. Entropy
  • 9.2. Omron Healthcare, Inc.
    • 9.2.1. Company Overview
    • 9.2.2. Company Snapshot
    • 9.2.3. Financial Overview
    • 9.2.4. Product Listing
    • 9.2.5. Entropy
  • 9.3. Aerogen
    • 9.3.1. Company Overview
    • 9.3.2. Company Snapshot
    • 9.3.3. Financial Overview
    • 9.3.4. Product Listing
    • 9.3.5. Entropy
  • 9.4. PARI GmbH
    • 9.4.1. Company Overview
    • 9.4.2. Company Snapshot
    • 9.4.3. Financial Overview
    • 9.4.4. Product Listing
    • 9.4.5. Entropy
  • 9.5. GF Health Products, Inc.
    • 9.5.1. Company Overview
    • 9.5.2. Company Snapshot
    • 9.5.3. Financial Overview
    • 9.5.4. Product Listing
    • 9.5.5. Entropy
  • 9.6. BMC Medical Co., Ltd.
    • 9.6.1. Company Overview
    • 9.6.2. Company Snapshot
    • 9.6.3. Financial Overview
    • 9.6.4. Product Listing
    • 9.6.5. Entropy
  • 9.7. Medtronic PLC
    • 9.7.1. Company Overview
    • 9.7.2. Company Snapshot
    • 9.7.3. Financial Overview
    • 9.7.4. Product Listing
    • 9.7.5. Entropy
  • 9.8. Invacare Corporation
    • 9.8.1. Company Overview
    • 9.8.2. Company Snapshot
    • 9.8.3. Financial Overview
    • 9.8.4. Product Listing
    • 9.8.5. Entropy
  • 9.9. Trudell Medical International
    • 9.9.1. Company Overview
    • 9.9.2. Company Snapshot
    • 9.9.3. Financial Overview
    • 9.9.4. Product Listing
    • 9.9.5. Entropy
  • 9.10. Nouvag AG
    • 9.10.1. Company Overview
    • 9.10.2. Company Snapshot
    • 9.10.3. Financial Overview
    • 9.10.4. Product Listing
    • 9.10.5. Entropy
  • 9.11. Timesco Healthcare Ltd.
    • 9.11.1. Company Overview
    • 9.11.2. Company Snapshot
    • 9.11.3. Financial Overview
    • 9.11.4. Product Listing
    • 9.11.5. Entropy
  • 9.12. LAICA S.p.A.
    • 9.12.1. Company Overview
    • 9.12.2. Company Snapshot
    • 9.12.3. Financial Overview
    • 9.12.4. Product Listing
    • 9.12.5. Entropy
  • 9.13. Vega Technologies Inc.
    • 9.13.1. Company Overview
    • 9.13.2. Company Snapshot
    • 9.13.3. Financial Overview
    • 9.13.4. Product Listing
    • 9.13.5. Entropy
  • 9.14. Besco Medical Limited
    • 9.14.1. Company Overview
    • 9.14.2. Company Snapshot
    • 9.14.3. Financial Overview
    • 9.14.4. Product Listing
    • 9.14.5. Entropy
  • 9.15. DeVilbiss Healthcare LLC
    • 9.15.1. Company Overview
    • 9.15.2. Company Snapshot
    • 9.15.3. Financial Overview
    • 9.15.4. Product Listing
    • 9.15.5. Entropy
  • 9.16. Feellife Health Inc.
    • 9.16.1. Company Overview
    • 9.16.2. Company Snapshot
    • 9.16.3. Financial Overview
    • 9.16.4. Product Listing
    • 9.16.5. Entropy
  • 9.17. Wellinks
    • 9.17.1. Company Overview
    • 9.17.2. Company Snapshot
    • 9.17.3. Financial Overview
    • 9.17.4. Product Listing
    • 9.17.5. Entropy
  • 9.18. Rossmax International Ltd
    • 9.18.1. Company Overview
    • 9.18.2. Company Snapshot
    • 9.18.3. Financial Overview
    • 9.18.4. Product Listing
    • 9.18.5. Entropy
  • 9.19. Novartis AG
    • 9.19.1. Company Overview
    • 9.19.2. Company Snapshot
    • 9.19.3. Financial Overview
    • 9.19.4. Product Listing
    • 9.19.5. Entropy
  • 9.20. AstraZeneca
    • 9.20.1. Company Overview
    • 9.20.2. Company Snapshot
    • 9.20.3. Financial Overview
    • 9.20.4. Product Listing
    • 9.20.5. Entropy
  • 9.21. GlaxoSmithKline plc
    • 9.21.1. Company Overview
    • 9.21.2. Company Snapshot
    • 9.21.3. Financial Overview
    • 9.21.4. Product Listing
    • 9.21.5. Entropy
    • 9.21.5. Entropy
  • 9.22. Lupin
    • 9.22.1. Company Overview
    • 9.22.2. Company Snapshot
    • 9.22.3. Financial Overview
    • 9.22.4. Product Listing
    • 9.22.5. Entropy
  • 9.23. Zydus Cadila
    • 9.23.1. Company Overview
    • 9.23.2. Company Snapshot
    • 9.23.3. Financial Overview
    • 9.23.4. Product Listing
    • 9.23.5. Entropy
  • 9.24. Teva Pharmaceutical Industries Ltd.
    • 9.24.1. Company Overview
    • 9.24.2. Company Snapshot
    • 9.24.3. Financial Overview
    • 9.24.4. Product Listing
    • 9.24.5. Entropy
  • 9.25. Boehringer Ingelheim International GmbH
    • 9.25.1. Company Overview
    • 9.25.2. Company Snapshot
    • 9.25.3. Financial Overview
    • 9.25.4. Product Listing
    • 9.25.5. Entropy
  • 9.26. Glenmark Pharmaceuticals Limited
    • 9.26.1. Company Overview
    • 9.26.2. Company Snapshot
    • 9.26.3. Financial Overview
    • 9.26.4. Product Listing
    • 9.26.5. Entropy
  • 9.27. Lepu Medical Technology (Beijing) Co., Ltd.
    • 9.27.1. Company Overview
    • 9.27.2. Company Snapshot
    • 9.27.3. Financial Overview
    • 9.27.4. Product Listing
    • 9.27.5. Entropy
  • 9.28. Promed Technology Co. Limited
    • 9.28.1. Company Overview
    • 9.28.2. Company Snapshot
    • 9.28.3. Financial Overview
    • 9.28.4. Product Listing
    • 9.28.5. Entropy
  • 9.29. HELTMAN Medikal A.S.
    • 9.29.1. Company Overview
    • 9.29.2. Company Snapshot
    • 9.29.3. Financial Overview
    • 9.29.4. Product Listing
    • 9.29.5. Entropy
    • 9.29.5. Entropy
  • 9.30. Pneuma Respiratory
    • 9.30.1. Company Overview
    • 9.30.2. Company Snapshot
    • 9.30.3. Financial Overview
    • 9.30.4. Product Listing
    • 9.30.5. Entropy
  • 9.31. Cipla Inc.
    • 9.31.1. Company Overview
    • 9.31.2. Company Snapshot
    • 9.31.3. Financial Overview
    • 9.31.4. Product Listing
    • 9.31.5. Entropy
  • 9.32. Microlife Corporation
    • 9.32.1. Company Overview
    • 9.32.2. Company Snapshot
    • 9.32.3. Financial Overview
    • 9.32.4. Product Listing
    • 9.32.5. Entropy
  • 9.33. Honsun
    • 9.33.1. Company Overview
    • 9.33.2. Company Snapshot
    • 9.33.3. Financial Overview
    • 9.33.4. Product Listing
    • 9.33.5. Entropy

10. KOL Views

11. Project Approach

12. About DelveInsight

13. Disclaimer & Contact Us